Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial
一项为期24周的多中心、随机、双盲、安慰剂对照的III期临床试验,旨在评估新型二肽基肽酶-4抑制剂替格列汀在韩国2型糖尿病患者中的疗效和安全性。
期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.12631
Hong, S; Park, C-Y; Han, K A; Chung, C H; Ku, B J; Jang, H C; Ahn, C W; Lee, M-K; Moon, M K; Son, H S; Lee, C B; Cho, Y-W; Park, S-W